Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Anavex Life Sciences Yönetim
Yönetim kriter kontrolleri 3/4
Anavex Life Sciences' CEO'su Chris Missling, Jul2013 tarihinde atandı, in görev süresi 11.25 yıldır. in toplam yıllık tazminatı $ 3.89M olup, şirket hissesi ve opsiyonları dahil olmak üzere 18% maaş ve 82% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.47% ine doğrudan sahiptir ve bu hisseler $ 7.10M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.8 yıl ve 10.4 yıldır.
Anahtar bilgiler
Chris Missling
İcra Kurulu Başkanı
US$3.9m
Toplam tazminat
| CEO maaş yüzdesi | 18.0% |
| CEO görev süresi | 11.3yrs |
| CEO sahipliği | 1.5% |
| Yönetim ortalama görev süresi | 2.8yrs |
| Yönetim Kurulu ortalama görev süresi | 10.4yrs |
Son yönetim güncellemeleri
Recent updates
Anavex Life Sciences: Short-Lived Spike On Latest Alzheimer's Data Not Surprising
Jul 29Companies Like Anavex Life Sciences (NASDAQ:AVXL) Are In A Position To Invest In Growth
Jul 17
Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation
Apr 01Here's Why We're Not At All Concerned With Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation
Sep 19We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow
May 10Companies Like Anavex Life Sciences (NASDAQ:AVXL) Can Afford To Invest In Growth
Jan 16We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth
Oct 01Anavex Life Sciences: Upcoming Readouts In Alzheimer's And Parkinson's Disease Dementia
Sep 19Anavex's Blarcamesine And Other Disease Modifying Treatments For Alzheimer's Disease
Sep 07Anavex Life Sciences GAAP EPS of -$0.16 beats by $0.01
Aug 09We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth
Jun 17Anavex: Increasing Shareholder Value Against All Odds
May 31Anavex's Blarcamesine And Cassava Sciences' Simufilam: The Stabilization Period For Alzheimer's Disease
Mar 23We're Not Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn
Mar 03Anavex 2-73: A Likely Effective Treatment For Alzheimer's Disease
Feb 09Anavex: Misunderstood Data And Possible Positive FDA Meeting Can Lead To Great Trade Opportunity
Feb 02Anavex: 2022 Has Major, Pivotal Catalysts
Jan 17Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business
Nov 16Alzheimer's - Cassava, Cortexyme Or Anavex: Who Will Come On Top?
Nov 05Anavex Life Sciences: Still Room To Run
Aug 29Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business
Jul 30Anavex: A Catalyst-Rich Year
Jul 05Virpax Pharmaceuticals, Anavex Life Sciences leads healthcare gainers; Aptevo Therapeutics, Intec Pharma among major losers
Jun 21Anavex Life outlines mechanism of ANAVEX2-73 and ANAVEX3-71 in treatment of Alzheimer's Disease
Jun 14Anavex Life's late-stage ANAVEX2-73 study in Alzheimer’s exceeds target enrollment
Jun 08Anavex, Cyclo Therapeutics, And Green Valley: Stalling The Progression Of Alzheimer's Disease
Apr 28Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business
Apr 16Anavex shares up 65% in morning trading continuing hot streak
Feb 04Anavex Life Sciences Corp.: 2021 Clinical Milestones Support Bullish Momentum
Jan 05CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$42m |
| Mar 31 2024 | n/a | n/a | -US$41m |
| Dec 31 2023 | n/a | n/a | -US$43m |
| Sep 30 2023 | US$4m | US$700k | -US$48m |
| Jun 30 2023 | n/a | n/a | -US$52m |
| Mar 31 2023 | n/a | n/a | -US$53m |
| Dec 31 2022 | n/a | n/a | -US$50m |
| Sep 30 2022 | US$7m | US$586k | -US$48m |
| Jun 30 2022 | n/a | n/a | -US$45m |
| Mar 31 2022 | n/a | n/a | -US$43m |
| Dec 31 2021 | n/a | n/a | -US$41m |
| Sep 30 2021 | US$9m | US$550k | -US$38m |
| Jun 30 2021 | n/a | n/a | -US$32m |
| Mar 31 2021 | n/a | n/a | -US$28m |
| Dec 31 2020 | n/a | n/a | -US$28m |
| Sep 30 2020 | US$2m | US$550k | -US$26m |
| Jun 30 2020 | n/a | n/a | -US$26m |
| Mar 31 2020 | n/a | n/a | -US$26m |
| Dec 31 2019 | n/a | n/a | -US$26m |
| Sep 30 2019 | US$3m | US$513k | -US$26m |
| Jun 30 2019 | n/a | n/a | -US$26m |
| Mar 31 2019 | n/a | n/a | -US$23m |
| Dec 31 2018 | n/a | n/a | -US$20m |
| Sep 30 2018 | US$3m | US$500k | -US$17m |
Tazminat ve Piyasa: Chris 'nin toplam tazminatı ($USD 3.89M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 2.40M ).
Tazminat ve Kazançlar: Chris 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Chris Missling (58 yo)
11.3yrs
Görev süresi
US$3,894,453
Tazminat
Dr. Christopher U. Missling, also known as the Chris, MS, Ph D., MBA, has been the Chief Executive Officer and President at Anavex Life Sciences Corp. since July 05, 2013 and also serves as its Director an...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 11.3yrs | US$3.89m | 1.47% $ 7.0m | |
| Principal Financial Officer & Treasurer | 9yrs | US$501.06k | 0.027% $ 128.5k | |
| Chief Scientific Officer | 2.8yrs | Veri yok | Veri yok | |
| VP of Corporate | no data | Veri yok | Veri yok | |
| Senior Vice President of Nonclinical Development | 3.4yrs | Veri yok | Veri yok | |
| Chief Medical Officer | 2.8yrs | Veri yok | Veri yok | |
| Head of Biostatistics | 1.6yrs | Veri yok | Veri yok | |
| Senior Vice President of Regulatory Affairs | less than a year | Veri yok | Veri yok | |
| Senior Vice President of Clinical Development | less than a year | Veri yok | Veri yok | |
| Senior VP & Head of Research and Development | less than a year | Veri yok | Veri yok |
2.8yrs
Ortalama Görev Süresi
Deneyimli Yönetim: AVXL 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.8 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 11.3yrs | US$3.89m | 1.47% $ 7.0m | |
| Independent Chairman | 3.4yrs | US$349.54k | Veri yok | |
| Member of the Scientific Advisory Board | 9.6yrs | Veri yok | Veri yok | |
| Member of the Scientific Advisory Board | 13.7yrs | Veri yok | Veri yok | |
| Member of the Scientific Advisory Board | 10.8yrs | Veri yok | Veri yok | |
| Member of the Scientific Advisory Board | 10.9yrs | Veri yok | Veri yok | |
| Member of the Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Independent Director | 11.8yrs | US$341.54k | 1.54% $ 7.3m | |
| Member of the Scientific Advisory Board | 10.4yrs | Veri yok | Veri yok | |
| Member of the Scientific Advisory Board | 9.6yrs | Veri yok | Veri yok | |
| Independent Director | 9.3yrs | US$341.54k | 0.0059% $ 28.0k | |
| Lead Independent Director | 6.6yrs | US$357.54k | Veri yok |
10.4yrs
Ortalama Görev Süresi
58yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: AVXL 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 10.4 yıldır).